Medicine Information

Adempa-M

Name: Adempa-M
Brand: Adempa-M
Rating: 4.5 (117 reviews)

Tablet5 mgAntidiabetic (SGLT2 Inhibitor), Cardioprotective, RenoprotectiveATC: A10BH04

Generic Name

Empagliflozin 5 mg tablet

Manufacturer

Acme Laboratories Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
adempa m 5 mg tablet	৳ 20.00	৳ 200.00

Description

Overview of the medicine

Adempa-M 5 mg Tablet contains Empagliflozin, an oral medication used for the treatment of type 2 diabetes mellitus. It belongs to a class of drugs called SGLT2 inhibitors. It works by causing the kidneys to remove sugar from the body through the urine. In addition to blood glucose control, it has demonstrated cardiovascular and renal benefits.

Uses & Indications

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (with reduced or preserved ejection fraction).

To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.

Dosage

Adults

Initial dose is 10 mg once daily. May be increased to 25 mg once daily based on glycemic control and tolerability. For heart failure or chronic kidney disease, the recommended dose is 10 mg once daily.

Elderly

No dosage adjustment is recommended based on age alone. However, renal function should be assessed before initiation and monitored during treatment.

Renal_impairment

Initial dose of 10 mg once daily. Not recommended to initiate in patients with eGFR < 20 mL/min/1.73m². Continue 10 mg for patients with eGFR < 20 if already on treatment.

How to Take

Take orally once daily in the morning, with or without food. Swallow the tablet whole; do not crush, cut, or chew.

Mechanism of Action

Empagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor. By inhibiting SGLT2, it reduces glucose reabsorption in the renal proximal tubules, leading to increased urinary glucose excretion (glucosuria) and consequent reduction in blood glucose levels. This mechanism is independent of insulin secretion and action. It also has diuretic and natriuretic effects.

Pharmacokinetics

Onset

Glucose-lowering effect observed within 30 minutes to 1 hour.

Excretion

Approximately half of the absorbed dose is excreted unchanged in the urine, and the remainder is excreted via feces (primarily as metabolites).

Half life

Approximately 12 hours.

Absorption

Rapidly absorbed after oral administration, peak plasma concentrations reached within 1.5 hours.

Metabolism

Primarily metabolized by glucuronidation via UGT enzymes (UGT1A3, UGT1A8, UGT1A9, UGT2B7, UGT2B10).

Side Effects

Contraindications

Hypersensitivity to empagliflozin or any excipients in the formulation.
Patients on dialysis or with severe renal impairment (eGFR < 15 mL/min/1.73m²) - not recommended for initiation.

Drug Interactions

Lithium

SGLT2 inhibitors may decrease serum lithium concentrations. Monitor serum lithium levels.

Diuretics (e.g., loop or thiazide diuretics)

May increase the risk of dehydration and hypotension.

Insulin and Insulin Secretagogues (e.g., sulfonylureas)

May increase the risk of hypoglycemia when co-administered. A lower dose of insulin or sulfonylurea may be required.

Storage

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Overdose

In case of an overdose, discontinue empagliflozin and initiate appropriate supportive treatment based on the patient's clinical status. Empagliflozin is not expected to be dialyzable.

Pregnancy & Lactation

Not recommended during the second and third trimesters of pregnancy due to potential adverse renal effects on the developing fetus. Avoid during breastfeeding as empagliflozin is excreted in animal milk and potential risks to infants are unknown.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

10 tablets per box30 tablets per box

Shelf Life

Typically 2-3 years from manufacturing date.

Availability

Pharmacies nationwide

Approval Status

Approved

Patent Status

Patented, varies by region; generic versions available in some markets post-patent expiry or through compulsory licensing

Clinical Trials

Empagliflozin has been extensively studied in several large-scale clinical trials, including EMPA-REG OUTCOME (cardiovascular outcomes in T2DM), EMPEROR-Reduced and EMPEROR-Preserved (heart failure), and EMPA-KIDNEY (chronic kidney disease). These trials demonstrated significant cardiovascular and renal benefits beyond glycemic control.

Lab Monitoring

Renal function (eGFR) should be assessed prior to initiation and periodically thereafter.
Blood glucose levels (fasting plasma glucose, HbA1c).
Lipid profile (less frequently).
Electrolytes if dehydration is suspected.

Doctor Notes

Educate patients on the importance of hydration to mitigate the risk of dehydration and UTIs.
Counsel patients about symptoms of euglycemic DKA and advise them to seek immediate medical attention if these occur.
Monitor renal function (eGFR) periodically, especially in elderly and those with pre-existing renal impairment.
Advise patients on proper genital hygiene to reduce the risk of mycotic infections.

Patient Guidelines

Take the medicine exactly as prescribed by your doctor.
Stay well hydrated by drinking plenty of fluids.
Be aware of symptoms of urinary tract or genital yeast infections and seek medical attention if they occur.
Report any unusual symptoms like nausea, vomiting, abdominal pain, or fatigue to your doctor, as these could be signs of ketoacidosis.

Missed Dose Advice

If a dose is missed, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at the same time.

Driving Precautions

Empagliflozin generally has no or negligible influence on the ability to drive and use machines. However, patients should be advised of the risk of dizziness and hypoglycemia (when used in combination with sulfonylureas or insulin) and advised to take precautions.

Lifestyle Advice

Maintain a balanced diet and regular exercise regimen as advised by your healthcare provider.
Monitor your blood glucose levels regularly.
Ensure adequate fluid intake to prevent dehydration, especially during illness or hot weather.

Alternative Medicines in Bangladesh

Similar medicines available in the market

Jardiance (Boehringer Ingelheim)Glyxambi (Empagliflozin/Linagliptin - Boehringer Ingelheim)Forxiga (Dapagliflozin - AstraZeneca)Invokana (Canagliflozin - Janssen)